--- title: "Faeth Therapeutics (FTH) news: offering" url: "https://aibio.space/companies/faeth-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "FTH offering news: Sensei Biotherapeutics acquires Faeth Therapeutics, agrees to $200 million private placement. Faeth Therapeutics, Inc." --- FTH Faeth Therapeutics, Inc. NASDAQ · United States # Faeth Therapeutics (FTH) news FTH offering news Company Updates · 2026-08-04 ## [Faeth Therapeutics reports $186.4 million in cash and securities after Sensei combination](https://aibio.space/news/faeth-therapeutics-reports-186-4-million-cash-securities-after-sensei/) Faeth reported a net loss of $16.0 million for the quarter ended June 30, 2026, and said topline data from its Phase 2 PIK-201 trial in endometrial cancer are expected by year-end. ## Latest Faeth Therapeutics news 1. 2026-02-18 Mergers [Sensei Biotherapeutics acquires Faeth Therapeutics, agrees to $200 million private placement](https://aibio.space/news/sensei-biotherapeutics-acquires-faeth-therapeutics-agrees-200-million/) Sensei Biotherapeutics closed its acquisition of Faeth Therapeutics on February 17, 2026, and agreed the same day to sell about $200 million of Series B preferred stock. The new investors would hold 54.3% of the company on an as-converted basis, and the lead drug's headline response rate comes from 15 patients. 2. 2025-07-09 Listings [Sensei Biotherapeutics (now Faeth Therapeutics) regains Nasdaq bid price compliance](https://aibio.space/news/sensei-biotherapeutics-now-faeth-therapeutics-regains-nasdaq-bid-price/) Nasdaq staff found the stock closed at $1.00 or more for 10 consecutive business days, from June 17, 2025 to July 1, 2025. 3. 2025-01-07 Listings [Sensei Biotherapeutics, Inc. (now Faeth Therapeutics, Inc.) gets 180 more days to meet Nasdaq bid price rule](https://aibio.space/news/sensei-biotherapeutics-inc-now-faeth-therapeutics-inc-gets-180-more/) Sensei Biotherapeutics told investors on January 7, 2025 that Nasdaq had moved its stock to the Capital Market and given it until July 7, 2025 to lift its share price above $1.00. Its 2023 annual report showed a $34,101 thousand net loss and cash that fell to $13,011 thousand at year end. ## Faeth Therapeutics at a glance - **Ticker**: FTH - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $186.4 million ### Related companies - [Alamar Biosciences](https://aibio.space/companies/alamar-biosciences/) NASDAQ: ALMR - [Intellia Therapeutics](https://aibio.space/companies/intellia-therapeutics/) NASDAQ: NTLA - [SORRENTO THERAPEUTICS INC](https://aibio.space/companies/sorrento-therapeutics/) OTC: SRNE - [BioAtla](https://aibio.space/companies/bioatla/) OTC: BCAB - [Longeveron](https://aibio.space/companies/longeveron/) NASDAQ: LGVN - [Range Impact](https://aibio.space/companies/range-impact/) OTC: RNGE - [Hemab Therapeutics Holdings](https://aibio.space/companies/hemab-therapeutics/) NASDAQ: COAG - [Enliven Therapeutics](https://aibio.space/companies/enliven-therapeutics/) NASDAQ: ELVN ### Also on NASDAQ - [Protara Therapeutics](https://aibio.space/companies/protara-therapeutics/) TARA - [Kodiak Sciences](https://aibio.space/companies/kodiak-sciences/) KOD - [Glucotrack](https://aibio.space/companies/glucotrack/) GCTK - [MapLight Therapeutics](https://aibio.space/companies/maplight-therapeutics/) MPLT - [Alector](https://aibio.space/companies/alector/) ALEC - [Eton Pharmaceuticals](https://aibio.space/companies/eton-pharmaceuticals/) ETON ## What Faeth Therapeutics does Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The filing is made by Sensei Biotherapeutics, Inc., which completed its acquisition of Faeth Therapeutics on February 17, 2026. The lead asset, PIKTOR, is an all-oral combination of serabelisib and sapanisertib that inhibits multiple nodes of the PI3K/AKT/mTOR pathway. It is in development for endometrial and breast cancer. PIKTOR is in an ongoing Phase 2 trial in second-line advanced endometrial cancer, with topline data anticipated by year-end 2026. In May 2026, the company announced that it had dosed the first patient in a Phase 1b trial in HR+/HER2- advanced breast cancer. The acquisition came with $200 million in gross proceeds from a private placement from a syndicate of investors. The company says the PI3K/AKT/mTOR pathway is dysregulated in up to 50% of all solid tumors, and that currently approved therapies each target only a single pathway node. | Product or program | What it is | Stage | |---|---|---| | PIKTOR | All-oral combination of serabelisib and sapanisertib, a multi-node PI3K/AKT/mTOR inhibitor | Phase 2 in endometrial cancer; Phase 1b in breast cancer | Summarised from the company's [10-K/A filed Jun 2, 2026](https://www.sec.gov/Archives/edgar/data/1829802/000119312526252637/d130328d10ka.htm). ## Faeth Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Net income (loss) | [-$21.1 million](https://www.sec.gov/Archives/edgar/data/1829802/000119312526132014/) | [-$30.2 million](https://www.sec.gov/Archives/edgar/data/1829802/000119312526132014/) | | Cash from operations | [-$20.5 million](https://www.sec.gov/Archives/edgar/data/1829802/000119312526132014/) | [-$24.7 million](https://www.sec.gov/Archives/edgar/data/1829802/000119312526132014/) | | Cash and equivalents | [$8.7 million](https://www.sec.gov/Archives/edgar/data/1829802/000119312526331562/) | [$10.0 million](https://www.sec.gov/Archives/edgar/data/1829802/000119312526132014/) | | Short-term investments | [$12.5 million](https://www.sec.gov/Archives/edgar/data/1829802/000119312526331562/) | [$31.3 million](https://www.sec.gov/Archives/edgar/data/1829802/000119312526132014/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $26.9 million, plus short-term investments of $159.5 million, $186.4 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Faeth Therapeutics Has Faeth Therapeutics raised money recently? Our latest story on this, dated Feb 18, 2026: "Sensei Biotherapeutics acquires Faeth Therapeutics, agrees to $200 million private placement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/sensei-biotherapeutics-acquires-faeth-therapeutics-agrees-200-million/). What is the ticker symbol of Faeth Therapeutics? Faeth Therapeutics, Inc. trades under the ticker FTH on NASDAQ. Where is Faeth Therapeutics listed? Faeth Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Faeth Therapeutics? The SEC Central Index Key (CIK) for Faeth Therapeutics, Inc. is 1829802. Its filings are on SEC EDGAR. How many shares does Faeth Therapeutics have outstanding? 25,840,425 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-04. Which country or territory is Faeth Therapeutics listed under? Our directory records Faeth Therapeutics, Inc. under United States. What does Faeth Therapeutics do? Our directory classifies Faeth Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Faeth Therapeutics? The ISIN recorded for Faeth Therapeutics, Inc. is US81728A2078. Does aibio.space cover Faeth Therapeutics? aibio.space lists Faeth Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Faeth Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Faeth Therapeutics develop? Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The filing is made by Sensei Biotherapeutics, Inc., which completed its acquisition of Faeth Therapeutics on February 17, 2026. What is PIKTOR from Faeth Therapeutics? PIKTOR: All-oral combination of serabelisib and sapanisertib, a multi-node PI3K/AKT/mTOR inhibitor Stage: Phase 2 in endometrial cancer; Phase 1b in breast cancer. Is Faeth Therapeutics profitable? Faeth Therapeutics, Inc. reported a net loss of $21.1 million for the fiscal year ended Dec 31, 2025, and used $20.5 million of cash in operations, per its annual report to the SEC. How much cash does Faeth Therapeutics have? $186.4 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Faeth Therapeutics (FTH) stock news? Our latest story on Faeth Therapeutics, dated Aug 4, 2026: "Faeth Therapeutics reports $186.4 million in cash and securities after Sensei combination". Faeth reported a net loss of $16.0 million for the quarter ended June 30, 2026, and said topline data from its Phase 2 PIK-201 trial in endometrial cancer are expected by year-end. [Source](https://aibio.space/news/faeth-therapeutics-reports-186-4-million-cash-securities-after-sensei/). ## Investor discussion: Faeth Therapeutics Members talk about Faeth Therapeutics (FTH). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Faeth Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-06-18 Financings Reported a financing. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/1829802/000119312526275791/d837676ds3asr.htm) 2. 2026-06-15 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,5.02,5.03,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1829802/000119312526270330/d144622dex991.htm) 3. 2026-06-10 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1829802/000119312526265879/d142513d8k.htm) 4. 2026-02-18 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.01,3.02,5.02,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1829802/000119312526056135/d112826dex991.htm) 5. 2025-10-30 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1829802/000119312525257621/d201536dex991.htm) 6. 2025-07-09 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1829802/000119312525157113/d64284d8k.htm) 7. 2025-06-13 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1829802/000119312525140329/d945713d8k.htm) 8. 2025-05-23 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1829802/000119312525125484/d13190d8k.htm) 9. 2025-05-06 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1829802/000095017025064525/snse-20250331.htm) 10. 2025-04-11 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1829802/000095017025053033/snse-def-proxy-fy2024_no.htm) 11. 2025-04-01 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1829802/000095017025048533/snse-pre-proxy-fy2024_no.htm) 12. 2025-01-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1829802/000119312525002920/d909848d8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:FTH on TradingView](https://www.tradingview.com/symbols/NASDAQ-FTH/). ## SEC filings and registration - **SEC name**: Faeth Therapeutics, Inc. - **CIK**: 1829802 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: FTH (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 701 TILLERY STREET #12 #1010, AUSTIN, TX, 78702 - **Phone**: 512-200-2982 - **Shares outstanding**: 25,840,425 as of 2026-07-30 (10-Q filed 2026-08-04) - **Former names**: Sensei Biotherapeutics, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1829802/000119312526394360/d174402d8k.htm) filed 2026-09-17 - [10-Q](https://www.sec.gov/Archives/edgar/data/1829802/000119312526331562/snse-20260630.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1829802/000119312526331563/d168633d8k.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1829802/000119312526314591/d68855d8k.htm) filed 2026-07-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1829802/000119312526276093/d82589d8k.htm) filed 2026-06-18 - [8-K](https://www.sec.gov/Archives/edgar/data/1829802/000119312526270330/d144622d8k.htm) filed 2026-06-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1829802/000119312526265879/d142513d8k.htm) filed 2026-06-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1829802/000119312526236820/d900837d8k.htm) filed 2026-05-22 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001829802), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Faeth Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker FTH, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Faeth Therapeutics, Inc. - **Ticker**: FTH - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US81728A2078 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-FTH/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/faeth-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Faeth Therapeutics (FTH) news: offering", 2026-10-31, https://aibio.space/companies/faeth-therapeutics/